Michigan Center, MI1 Active Studies

Pulmonary Fibrosis Clinical Trials in Michigan Center, MI

Find 1 actively recruiting pulmonary fibrosis clinical trials in Michigan Center, MI. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
102
Enrolling

Recruiting Pulmonary Fibrosis Studies in Michigan Center

About Pulmonary Fibrosis Clinical Trials in Michigan Center

Pulmonary fibrosis is a condition in which the lung tissue becomes damaged and scarred, making it difficult for the lungs to function properly. Idiopathic pulmonary fibrosis (IPF) is the most common form with unknown cause. Antifibrotic medications can slow progression, and lung transplant may be considered.

There are currently 1 pulmonary fibrosis clinical trials recruiting participants in Michigan Center, MI. These studies are seeking a combined 102 participants. Research is being sponsored by Daewoong Pharmaceutical Co. LTD.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Fibrosis Clinical Trials in Michigan Center — FAQ

Are there pulmonary fibrosis clinical trials in Michigan Center?

Yes, there are 1 pulmonary fibrosis clinical trials currently recruiting in Michigan Center, MI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Michigan Center?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Michigan Center research site will contact you about next steps.

Are clinical trials in Michigan Center free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Michigan Center studies also compensate for your time and travel.

What pulmonary fibrosis treatments are being tested?

The 1 active trials in Michigan Center are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary fibrosis.

Data updated March 2, 2026 from ClinicalTrials.gov